- •Due to production shortages, BCG has been precluded from many urological practices.
- •Gem/Doce is a safe and effective treatment for NMIBC.
- •Further prospective evaluation is underway.
Patients and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.The Journal of urology. 2017; 198: 552-559
- Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.The Journal of urology. 2002; 168: 1964-1970
- Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.The Journal of urology. 2000; 163: 1124-1129
- Severe Infectious Complications of Intravesical Bacillus Calmette-Guerin: A Case Series of 10 Patients.Urology. 2020; 137: 79-83
- Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer.Bladder Cancer. 2019; 5
- The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.The Journal of urology. 2006; 175: 1634-1640
- The effect of age on the efficacy of maintenance bacillus calmette-guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: Results from EORTC genito-urinary group study 30911.European Urology. 2014; 66: 694-701
- Aging and Innate Immunity.Immunity. 2006; 24: 491-494
- Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.BJU International. 2013; 111: 984-987
- Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients.Transplantation. 2003; 76: 1514-1516
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.European urology. 2019; 76: 639-657
Flanigan RC, Edney MT, Maddox-Smith A, et al: BCG Shortage Info. American Urological Association 2019: 1. Available at: https://www.auanet.org/about-us/bcg-shortage-info.
- Messing EM: The BCG Shortage.Bladder Cancer. 2017; 3: 227-228
- Intravesical gemcitabine for superficial bladder cancer: Rationale for a new treatment option.BJU International. 2005; 96: 970-976
- SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus calmette-guérin.Journal of Urology. 2013; 190: 1200-1204
- Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.Current cancer drug targets. 2003; 3: 193-203
- Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.Journal of Urology. 2013; 189: 834-839
- The safety and efficacy of gemcitabine for the treatment of bladder cancer.Expert review of anticancer therapy. 2016; 16: 255-271
- Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; Results of a phase II study in non-chemotherapy-pretreated patients.British Journal of Cancer. 1998; 78: 1342-1345
- Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.The Journal of urology. 2019; (101097JU0000000000000688)
- Sequential Intravesical Gemcitabine and Docetaxel for BCG-Naïve High-Risk Non-Muscle Invasive Bladder Cancer. PD26-03.Journal of Urology. 2022; 207: e488
- Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.The New England journal of medicine. 2017; 376: 1401-1403
- Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes.BJU International. 2018; 122: 898-908
- Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.The Journal of urology. 2003; 169: 90-95
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer.European Urology. 2009; 56: 247-256
- MP43-04 CONTEMPORARY OUTCOMES OF NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH INDUCTION BCG.Journal of Urology. 2019; 201 (e618–e618)
- Treatment of high-grade non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: Results of the phase III clinical trial (NIMBUS).Journal of Clinical Oncology. 2020; 38: 436
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder.New England Journal of Medicine. 1991; 325: 1205-1209
- Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.Urologic Oncology: Seminars and Original Investigations. 1995; 1: 119-126
- Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.Urologic oncology. 2020;